Ajer Jeffrey Robert
Known title: EVP, Chief Commercial OfficerCIK: 0001557533
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
BioMarin Reports Phase 3 Pompe Data, Expands AI Partnership. BioMarin presented phase‑3 results for its Pompe disease therapy POMBILITI® combined with OPFOLDA® at the World Muscle Society Congress, reporting sustained efficacy and no new safety signals. The company also announced a partnership with Profluent to use AI for designing enzyme therapies, and a license agreement with Ascendis Pharma that includes royalties on future sales. These developments highlight BioMarin’s focus on expanding its therapeutic pipeline and leveraging technology partnerships.
Transaction History
| NKTR | ▲ Buy | Grant | 2,000 | $0 | 9/23/2026 | View on chart |
| BMRN | ▼ Sell | Open Market | 5,000 | $415K | 5/2/2024 | View on chart |
| BMRN | ▲ Buy | Grant | 300 | $21K | 4/30/2024 | View on chart |
| BMRN | ▼ Sell | Tax Withholding | 22,580 | $1.9M | 3/15/2024 | View on chart |
| BMRN | ▼ Sell | Open Market | 4,000 | $348K | 3/5/2024 | View on chart |
| BMRN | ▲ Buy | Grant | 9,338 | $0 | 2/27/2024 | View on chart |
| BMRN | ▲ Buy | Grant | 6,465 | $0 | 2/27/2024 | View on chart |
| BMRN | ▲ Buy | Grant | 21,440 | $0 | 2/27/2024 | View on chart |
| NKTR | ▼ Sell | Open Market | 4,359 | $3K | 9/18/2023 | View on chart |
| BMRN | ▼ Sell | Open Market | 5,000 | $450K | 8/16/2023 | View on chart |
| BMRN | ▲ Buy | Grant | 318 | $21K | 4/28/2023 | View on chart |
| BMRN | ▼ Sell | Tax Withholding | 20,510 | $1.9M | 3/16/2023 | View on chart |
| BMRN | ▼ Sell | Tax Withholding | 3,971 | $348K | 3/15/2023 | View on chart |
| BMRN | ▲ Buy | Grant | 10,110 | $0 | 3/15/2023 | View on chart |
| BMRN | ▲ Buy | Grant | 10,380 | $0 | 2/28/2023 | View on chart |
| BMRN | ▲ Buy | Grant | 7,629 | $0 | 2/28/2023 | View on chart |
| BMRN | ▲ Buy | Grant | 20,760 | $0 | 2/28/2023 | View on chart |
| BMRN | ▲ Buy | Option Exercise | 49,000 | $3.3M | 1/25/2023 | View on chart |
| BMRN | ▼ Sell | Open Market | 44,825 | $5.2M | 1/25/2023 | View on chart |
| BMRN | ▼ Sell | Open Market | 4,175 | $485K | 1/25/2023 | View on chart |
| BMRN | ▼ Sell | Open Market | 3,000 | $258K | 11/2/2022 | View on chart |
| NKTR | ▼ Sell | Open Market | 4,198 | $13K | 9/23/2022 | View on chart |
| NKTR | ▲ Buy | Grant | 10,200 | $0 | 9/16/2022 | View on chart |
| BMRN | ▼ Sell | Open Market | 3,000 | $287K | 8/11/2022 | View on chart |
| BMRN | ▼ Sell | Tax Withholding | 7,021 | $544K | 6/3/2022 | View on chart |
| BMRN | ▼ Sell | Open Market | 1,308 | $103K | 5/26/2022 | View on chart |
| BMRN | ▲ Buy | Grant | 340 | $21K | 4/29/2022 | View on chart |
| BMRN | ▼ Sell | Open Market | 1,180 | $97K | 4/13/2022 | View on chart |
| BMRN | ▼ Sell | Open Market | 1,381 | $110K | 3/30/2022 | View on chart |
| BMRN | ▼ Sell | Open Market | 1,618 | $129K | 3/29/2022 | View on chart |
| BMRN | ▼ Sell | Open Market | 6,129 | $501K | 3/23/2022 | View on chart |
| BMRN | ▼ Sell | Open Market | 2,073 | $168K | 3/22/2022 | View on chart |
| BMRN | ▼ Sell | Tax Withholding | 1,287 | $104K | 3/16/2022 | View on chart |
| BMRN | ▼ Sell | Tax Withholding | 8,418 | $659K | 3/15/2022 | View on chart |
| BMRN | ▲ Buy | Grant | 11,940 | $0 | 3/15/2022 | View on chart |
| BMRN | ▲ Buy | Grant | 9,370 | $0 | 3/8/2022 | View on chart |
| BMRN | ▼ Sell | Open Market | 2,739 | $202K | 10/26/2021 | View on chart |
| NKTR | ▲ Buy | Grant | 10,200 | $0 | 9/22/2021 | View on chart |
| NKTR | ▼ Sell | Open Market | 3,665 | $65K | 9/22/2021 | View on chart |
| BMRN | ▲ Buy | Grant | 342 | $21K | 4/30/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
NKTR receives mixed analyst coverage and pipeline focus
Several research firms started coverage on Nektar Therapeutics this week. UBS began coverage with a neutral rating and a $53 price target, while Leerink issued an outperform rating and set a $130 target, and Raymond James launched coverage with a market‑perform view. BTIG kept a buy rating with a $178 target. At the same time, commentary pieces note the company's pipeline progress and recent rezpegaldesleukin data, suggesting potential long‑term value and possible undervaluation.
NKTR receives mixed analyst coverage and pipeline focus. Several research firms started coverage on Nektar Therapeutics this week. UBS began coverage with a neutral rating and a $53 price target, while Leerink issued an outperform rating and set a $130 target, and Raymond James launched coverage with a market‑perform view. BTIG kept a buy rating with a $178 target. At the same time, commentary pieces note the company's pipeline progress and recent rezpegaldesleukin data, suggesting potential long‑term value and possible undervaluation.